Research window: 9–16 October 2026. Published on 23 October 2026 as a catch-up update.
Two human trials examine vascular function, cognition and strength. Neither establishes longer life or prevention of age-related disease.
Does this change current advice?
These findings support further research, without establishing a reason for routine supplementation. Primary outcomes, tolerability and trial registration matter when assessing promising headlines.
1. Urolithin A: primary vascular result null
Read the urolithin A randomised trial — 9 October 2026, JAMA Network Open.
A double-blind, placebo-controlled trial randomised 50 adults aged 40–64 with obesity to 1,000 mg/day urolithin A or placebo for four weeks; 43 completed follow-up.
The primary outcome, brachial artery flow-mediated dilation, did not improve significantly versus placebo. Mean changes were 1.3 percentage points with supplementation and 0.3 with placebo. Other peripheral vascular measures were also null. Brain blood-oxygen responses during cognitive tasks increased, but task performance did not improve.
What is new and why it matters: Controlled human vascular evidence helps test claims associated with mitochondrial health. The secondary brain-response signal needs interpretation alongside the negative primary result.
Practical takeaway and limitations: This does not demonstrate better cognition, dementia prevention or lifespan extension. The small sample and four-week duration limit efficacy and long-term safety conclusions.
Funding and disclosures: American Heart Association and Reynolds Foundation support; no conflicts reported.
Worth reading in full: Top read, especially to compare primary and secondary findings.
2. Ginseng plus CaHMB: modest functional benefits, confirmation needed
Read the ginseng–CaHMB trial — 13 October 2026, Aging Clinical and Experimental Research. Peer-reviewed accepted manuscript, subject to further editing.
A single-centre trial randomised 136 adults aged at least 65 with cognitive impairment and sarcopenia to an enriched nutritional formula or nutritionally matched control for six months. Participants and outcome assessors were blinded.
Adjusted differences favoured supplementation by 1.40 MMSE points, 1.71 MoCA points and 1.44 kg of handgrip strength. The muscle-mass result was sensitive to missing-data assumptions. Possibly product-related complaints were more frequent, mainly bitterness and tolerability; no serious adverse events occurred.
What is new and why it matters: The study assesses cognitive and strength outcomes together in people with both impairments.
Practical takeaway and limitations: Clinical relevance remains uncertain. Retrospective registration, a principal per-protocol analysis and the combined formulation limit confidence and prevent attributing benefit to either ingredient alone.
Funding and disclosures: Public grants supported the work. Guangzhou Enternutr developed and supplied formulations; three authors were company-affiliated.
Worth reading in full: Second priority, especially registration, sensitivity analyses and commercial involvement.
Educational research summary, not individual treatment advice. Findings apply to the populations and formulations studied. Source links checked: 23 October 2026. This is a focused roundup, not a systematic review.